Evaluation of the effectiveness of Alflutop in the targeted therapy of dorsopathies of the lumbosacral localization in patients with post-COVID syndrome (observational study ALCOR)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the fact that the number of new cases of SARS-CoV-2 infection has significantly decreased recently, the clinical manifestations of the consequences of the infection and, above all, the pain syndrome, remain an urgent problem for practitioners. The purpose of an open observational study was to analyze the efficacy and tolerability of Alflutop in the treatment of dorsopathies of the lumbosacral localization (DLL) in patients with post-COVID syndrome (PCS). Material and methods. The study included 75 patients with DLL and PCS who received Alflutop 2 ml every other day 10 injections. The values of VAS pain, LANSS, digital pressor algometry, Post-COVID-19 Functional Status (PCFS) questionnaire were analyzed. The total duration of follow-up was 3 months and 20 days. Results. The severity of the pain syndrome changed significantly after 1 month and 20 days (42,3±8,4 vs 33,1±7,0 mm, p <0,05), and following the end of observation it decreased to the level of «insignificant» (15,1 ±8,8 mm, p <0,05). LANSS questionnaire: significant decrease after 3 months and 20 days (14,6±2,3 vs 9,4± 1,8 points). We registered a significant increase in the local pain threshold after 1 month and 20 days (4,56±1,3 kg/cm2), the maximum after the study completion 5,46±1,8 kg/cm2. The suprasegmental pain threshold changed significantly in relation to the initial value only at the finцэl visit 6,08±1,9 kg/cm2. At the end of therapy, there was a significant improvement in the functional status of the examined category of patients (PCFS: 3,0±0,4 vs 1,9±0,8 points). Conclusions. The use of Alflutop in patients with DLL and PCS can reduce the severity of pain and improve the functional status of patients in a short time from the start of therapy.

Full Text

Restricted Access

About the authors

Sergey A. Zhivolupov

S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation

Dr. med. habil., professor, professor of the Department of nervous diseases

Igor N. Samartsev

S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation

Dr. med. habil., associate professor of the Department of nervous diseases

Vladimir V. Ponomarev

Belarusian Medical Academy of Postgraduate Education

Dr. med. habil., professor, head of the Department of neurology and neurosurgery

References

  1. Самарцев И.Н., Живолупов С.А. Софизмы в современной доктрине рациональной терапии хронической боли в нижней части спины и пути их преодоления. Нервные болезни. 2020; 4: 25-31. https://dx.doi.org/10.24412/22260757-2020-12240. EDN: SXXTHC.
  2. Ma K., Zhuang Z.G., Wang L. et al. The Chinese Association for the Study of Pain (CASP): Consensus on the assessment and management of chronic nonspecific low back pain. Pain Res Manag. 2019; 2019: 8957847. https://dx.doi.org/10.1155/2019/8957847.
  3. Korompoki E., Gavriatopoulou M., Hicklen R. et al. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J. Infect. 2021; 83(1): 1-16. https://dx.doi.org/10.1016/j.jinf.2021.05.004.
  4. Ellul M., Benjamin L., Singh B. et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767-83. https://dx.doi.org/10.1016/s1474-4422(20)30221-0.
  5. Jensen M., Karoly P., Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986; 27(1): 1 17-26. https://dx.doi.org/10.1016/0304-3959(86)90228-9.
  6. Юсупова Д.Г., Супонева Н.А., Зимин А.А. с соавт. Валидация Лидской шкалы оценки нейропатической боли (LANSS) в России. Нервно-мышечные болезни. 2018; 8(3): 43-50. [Yusupova D.G., Suponeva N.A., Zimin A.A. et al. Validation of the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (LANSS) in Russia. Nervno-myshechnyye bolezni = Neuromuscular Diseases. 2018; 8(3): 43-50 (In Russ.)]. https://dx.doi.org/10.17650/2222-8721-2018-8-3-43-50. EDN: YLPRTF.
  7. Klok F., Boon G., Barco S. et al. The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID- 19. Eur Respir J. 2020; 56(1): 2001494. https://dx.doi.org/10.1183/13993003.01494-2020.
  8. Юнкеров В.И., Григорьев С.Г. Математико-статистическая обработка данных медицинских исследований. СПб: ВМедА. 2005; 292 c.
  9. Weng L.M., Su X., Wang X.Q. Pain symptoms in patients with coronavirus disease (COVID-19): A literature review. J. Pain Res. 2021; 14: 147-59. https://dx.doi.org/10.2147/JPR.S269206.
  10. B i levi ciute-Ljungar I., Norrefalk J.R., Borg K. Pain burden in post-COVID-19 syndrome following mild COVID-19 infection. J. Clin Med. 2022; 11(3): 771. https://dx.doi.org/10.3390/jcm11030771.
  11. Vanichkachorn G., Newcomb R., Cowl C.T. et al. Post-COVID-19 syndrome (Long Haul syndrome): Description of a multidisciplinary clinic at Mayo Clinic and characteristics of the initial patient cohort. Mayo Clin Proc. 2021; 96(7): 1782-91. https://dx.doi.org/10.1016Zj.mayocp.2021.04.024.
  12. Ellul M., Benjamin L., Singh B. et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19(9): 767-83. https://dx.doi.org/10.1016/s1474-4422(20)30221-0.
  13. Goudman L., De Smedt A., Noppen M., Moens M. Is central sensitisation the missing link of persisting symptoms after COVID-19 infection? J. Clin Med. 2021; 10(23): 5594. https://dx.doi.org/10.3390/jcm10235594.
  14. La Marca A., Busani S., Donno V. et al. Testicular pain as an unusual presentation of COVID-19: A brief review of SARS-CoV-2 and the testis. Reprod Biomed Online. 2020; 41(5): 903-6. https://dx.doi.org/10.1016/j.rbmo.2020.07.017.
  15. Самарцев И.Н., Живолупов С.А., Баранцевич Е.Р., Данилов А.Б. Оценка терапевтической эффективности Алфлутопа в комплексном лечении пациентов с хронической болью в нижней части спины (наблюдательное исследование ЦЕЙТНОТ). Журнал неврологии и психиатрии имени С.С. Корсакова. 2021; 121(2): 24-30. https://dx.doi.org/10.17116/jnevro202112102124. EDN: TTJVJW.
  16. Каратеев А.Е. Биоактивный концентрат мелкой морской рыбы: оценка эффективности и безопасности препарата на основании анализа 37 клинических исследований. Современная ревматология. 2020; 14(4): 111-124. https://dx.doi.org/10.14412/1996-7012-2020-4-111-124. EDN: JEPCAS.
  17. Левин О.С., Олюнин Д.Ю., Голубева Л.В. Эффективность Алфлутопа при хронической вертеброгенной люмбоишиалгии по данным двойного слепого плацебо-контролируемого исследования. Научно-практическая ревматология. 2004; 42(4): 80-84. [Levin O.S., Olyunin D.Yu., Golubeva L.V. Alflutop efficacy in chronic vertebrogenous lumbar ischialgia. A double blind placebo controlled study. 2004; 42(4): 80-84 (In Russ.)]. EDN: QCXEIB.
  18. Живолупов С.А., Самарцев И.Н., Пономарев В.В. Количественная оценка и анализ центральных механизмов анальгетического эффекта Алфлутопа у пациентов с хронической болью в нижней части спины. Журнал неврологии и психиатрии имени С.С. Корсакова. 2021; 121(10): 38-44. https://dx.doi.org/10.17116/jnevro202112110138. EDN: XUWUDR.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies